Researchers have developed a vaccine against the COVID-19 coronavirus which induced the rapid production of antibodies in mice.
List view / Grid view
Filter the results
Recombinant angiotensin converting enzymes (ACE2) reduced infection and viral growth in cell cultures and organoids by acting as a decoy for SARS-CoV-2.
Researchers have created an accurate mouse model of Duchenne muscular dystrophy (DMD), showing that TGFβ is a potential target for the condition.
The University of Alabama at Birmingham (UAB) will run the pre-clinical trials of Altimmune’s intranasal COVID-19 vaccine candidate, AdCOVID.
A new CAR T-cell therapy has been created by researchers which targets three proteins on leukaemia cells and has shown success in pre-clinical trials.
Researchers demonstrated that ABCC4 is essential to signalling in the SHH subgroup of medulloblastomas and when expression was reduced in mice, the tumours shrank.
A collaboration aims to utilise a compound library of 15,000 clinically-ready molecules and screen then against three COVID-19 targets.
Drug Target Review rounds up the latest announcements regarding funding for research into COVID-19 treatments and vaccines.
Researchers have developed a new CAR T-cell therapy that targets an antigen called glycipan-1 (GPC1), showing efficacy at fighting solid tumours in mice.
Cryogenic electron microscopy revealed that the vitamin B12 transporter on Mycobacterium tuberculosis acts like a non-selective sluice, transporting both the vitamin and antibiotics.
Researchers captured 13,000 images of a mouse norovirus using an electron microscope and compiled the images to reveal the structure of the virus.
In light of the COVID-19 pandemic, the creators of the Clinical Research Navigator (CRN) tool have offered free access to their system for biomedical researchers.
A new study has shown that the role of T cell-suppressing dendritic cells can be reversed in mice, indicating that immunotherapies could be improved with this method.
Researchers have demonstrated that Nafamostat mesylate (Fusan) can inhibit SARS-CoV-2 Spike protein-initiated membrane fusion at concentrations likely achievable and safe in patients.
Researchers have used high-throughput screening to discover the best combinations of purified cannabinoids against gastrointestinal cancer cells.